Precision BioSciences, Inc. DTIL

DTIL Company Overview

Precision BioSciences, Inc. is a clinical-stage biotechnology company focused on developing in vivo gene editing therapies and other genomic medicines. The company operates primarily within the biotechnology, gene editing, and genetic medicine industries, with research efforts centered on treating serious diseases through targeted genome engineering. Precision BioSciences is best known for its proprietary ARCUS genome editing platform, a gene editing technology derived from a naturally occurring homing endonuclease. The company’s development programs have historically focused on immuno-oncology, genetic diseases, and hepatitis B, although its strategic emphasis has increasingly shifted toward in vivo gene editing applications.

The company generates value primarily through research and development partnerships, licensing arrangements, and advancement of proprietary therapeutic candidates. Precision BioSciences has collaborated with larger pharmaceutical and biotechnology companies to support development and commercialization efforts. Founded in 2006 and headquartered in Durham, North Carolina, the company evolved from an early-stage genome engineering platform developer into a publicly traded biotechnology company listed on Nasdaq under the ticker DTIL. Over time, the company has narrowed its operational focus to prioritize programs with potential for differentiated therapeutic delivery and editing precision.